128 related articles for article (PubMed ID: 6360329)
1. Complete response of metastasized adrenal cortical carcinoma with o,p'-DDD. Case report and literature review.
Boven E; Vermorken JB; van Slooten H; Pinedo HM
Cancer; 1984 Jan; 53(1):26-9. PubMed ID: 6360329
[TBL] [Abstract][Full Text] [Related]
2. [Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels].
Heilmann P; Wagner P; Nawroth PP; Ziegler R
Med Klin (Munich); 2001 Jul; 96(7):371-7. PubMed ID: 11494911
[TBL] [Abstract][Full Text] [Related]
3. o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.
Hogan TF; Citrin DL; Johnson BM; Nakamura S; Davis TE; Borden EC
Cancer; 1978 Nov; 42(5):2177-81. PubMed ID: 719602
[TBL] [Abstract][Full Text] [Related]
4. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements.
Robinson BG; Hales IB; Henniker AJ; Ho K; Luttrell BM; Smee IR; Stiel JN
Clin Endocrinol (Oxf); 1987 Oct; 27(4):437-44. PubMed ID: 2830062
[TBL] [Abstract][Full Text] [Related]
5. Treatment of an adrenal cortical carcinoma with a combination of o,p'-DDD and aminoglutethimide.
Scott RD
Postgrad Med J; 1975 Jan; 51(591):35-7. PubMed ID: 1161676
[TBL] [Abstract][Full Text] [Related]
6. Toxicity, ultrastructural effects, and metabolic studies with 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane(o,p'-DDD) and its methyl analog in the guinea pig and rat.
Jensen BL; Caldwell MW; French LG; Briggs DG
Toxicol Appl Pharmacol; 1987 Jan; 87(1):1-9. PubMed ID: 3798445
[TBL] [Abstract][Full Text] [Related]
7. Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.
Kasperlik-Zaluska AA; Cichocki A
J Exp Ther Oncol; 2005; 5(2):125-32. PubMed ID: 16471038
[TBL] [Abstract][Full Text] [Related]
8. The distribution of o,p'-DDD (mitotane) among serum lipoproteins in normo- and hypertriglyceridemia.
Gebhardt DO; Moolenaar AJ; van Seters AP; van der Velde EA; Gevers Leuven JA
Cancer Chemother Pharmacol; 1992; 29(4):331-4. PubMed ID: 1537084
[TBL] [Abstract][Full Text] [Related]
9. [Hemorrhage into the peritoneum in the course of treatment of adrenocortical carcinoma with o,p'-DDD and 5-fluorouracil].
Kasperlik-Zaluska A; Migdalska B
Endokrynol Pol; 1976; 27(1):111-5. PubMed ID: 1253752
[No Abstract] [Full Text] [Related]
10. Metastatic adrenal cortical carcinoma. Documented cure with combined chemotherapy.
Ostuni JA; Roginsky MS
Arch Intern Med; 1975 Sep; 135(9):1257-8. PubMed ID: 1164127
[TBL] [Abstract][Full Text] [Related]
11. Complete remission of metastasized adrenocortical carcinoma under o,p'-DDD.
Kornely E; Schlaghecke R
Exp Clin Endocrinol; 1994; 102(1):50-3. PubMed ID: 8005209
[TBL] [Abstract][Full Text] [Related]
12. Treatment of adrenal cortical carcinoma with mitotane: outcome and complications.
Lim MC; Tan YO; Chong PY; Cheah JS
Ann Acad Med Singap; 1990 Jul; 19(4):540-4. PubMed ID: 2171414
[TBL] [Abstract][Full Text] [Related]
13. Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p'-DDD] and its p,p'- and m,p'-isomers.
Cai W; Benitez R; Counsell RE; Djanegara T; Schteingart DE; Sinsheimer JE; Wotring LL
Biochem Pharmacol; 1995 May; 49(10):1483-9. PubMed ID: 7763292
[TBL] [Abstract][Full Text] [Related]
14. A high-pressure liquid chromatographic method for measuring mitotane [1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethane] and its metabolite 1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethene in plasma.
Andersen A; Warren DJ; Nome O; Vesterhus L; Slørdal L
Ther Drug Monit; 1995 Oct; 17(5):526-31. PubMed ID: 8585118
[TBL] [Abstract][Full Text] [Related]
15. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
Dickstein G; Shechner C; Arad E; Best LA; Nativ O
J Clin Endocrinol Metab; 1998 Sep; 83(9):3100-3. PubMed ID: 9745410
[TBL] [Abstract][Full Text] [Related]
16. o,p'DDD therapy in invasive adrenocortical carcinoma.
Becker D; Schumacher OP
Ann Intern Med; 1975 May; 82(5):677-9. PubMed ID: 1137262
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o,p'-DDD in human adrenal zona fasciculata/reticularis.
Lindhe O; Skogseid B; Brandt I
J Clin Endocrinol Metab; 2002 Mar; 87(3):1319-26. PubMed ID: 11889204
[TBL] [Abstract][Full Text] [Related]
18. Adrenal cortical carcinoma: a case report.
Judy JC; Scardino PL
J Med Assoc Ga; 1973 Nov; 62(11):377-9. PubMed ID: 4128251
[No Abstract] [Full Text] [Related]
19. o,p'-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis.
Touitou Y; Moolenaar AJ; Bogdan A; Auzéby A; Luton JP
Eur J Clin Pharmacol; 1985; 29(4):483-7. PubMed ID: 4092727
[TBL] [Abstract][Full Text] [Related]
20. Adrenocortical carcinoma responded to treatment with o,p'-DDD--a case report.
Naruse T; Koike A; Kato K; Ishii T; Suzumura K; Matsumoto K
Endocrinol Jpn; 1984 Aug; 31(4):417-26. PubMed ID: 6097439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
